Inhibikase Therapeutics (IKT) Debt to Equity (2020 - 2025)
Inhibikase Therapeutics (IKT) has disclosed Debt to Equity for 6 consecutive years, with $0.0 as the latest value for Q2 2025.
- Quarterly Debt to Equity fell 98.41% to $0.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $0.0 through Jun 2025, down 98.41% year-over-year, with the annual reading at $0.0 for FY2024, 91.48% down from the prior year.
- Debt to Equity for Q2 2025 was $0.0 at Inhibikase Therapeutics, down from $0.0 in the prior quarter.
- The five-year high for Debt to Equity was $0.03 in Q1 2021, with the low at -$0.27 in Q3 2024.
- Average Debt to Equity over 5 years is -$0.01, with a median of $0.01 recorded in 2023.
- Peak annual rise in Debt to Equity hit 292.9% in 2024, while the deepest fall reached 2857.86% in 2024.
- Over 5 years, Debt to Equity stood at $0.01 in 2021, then skyrocketed by 31.06% to $0.01 in 2022, then skyrocketed by 97.21% to $0.01 in 2023, then plummeted by 91.48% to $0.0 in 2024, then tumbled by 59.31% to $0.0 in 2025.
- According to Business Quant data, Debt to Equity over the past three periods came in at $0.0, $0.0, and $0.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.